Last reviewed · How we verify
NCT03042754
Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals
NA trial testing XpertMTB/RIF in Tuberculosis in 150 participants. Participants enrolled and being followed up; not accepting new ones.
1 December 2030
Quick facts
| Lead sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 150 |
| Start date | 6 June 2011 |
| Primary completion | 1 December 2030 |
| Estimated completion | 1 December 2030 |
| Sites | 4 locations across Thailand |
Drugs / interventions tested
- XpertMTB/RIF
Conditions studied
- Tuberculosis — all drugs for Tuberculosis →
Sponsor
The HIV Netherlands Australia Thailand Research Collaboration — full company profile →
Who can join
18 and older, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early diagnosis can contribute to good treatment outcomes and isolate infection control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03042754
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis
Currently open trials in the same condition.
- NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
- NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
- NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
- NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
- NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting
Other The HIV Netherlands Australia Thailand Research Collaboration trials
Trials by the same sponsor.
- NCT04552015 — Microneedles for Diagnosis of LTBI · NA · terminated
- NCT03731559 — Efficacy, Safety and Pharmacokinetics of DTG with RIF · Phase 2 · recruiting
- NCT03835832 — Self-Assessment Tuberculin Skin Test · completed
- NCT03727152 — Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolu · Phase 3 · completed
- NCT03037151 — Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03042754 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The HIV Netherlands Australia Thailand Research Collaboration
- Last refreshed: 17 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042754.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing